Long-term response to zonisamide in patients with West syndrome.
The long-term effectiveness of zonisamide (ZNS) was evaluated in 11 patients with West syndrome (7 symptomatic) who had cessation of spasms with ZNS monotherapy. During the follow-up period (24 to 79 months, mean = 53 months), this response was maintained in 7 patients (3 symptomatic, relapse rate = 36%), including 2 children in whom ZNS was successfully discontinued. No serious adverse reactions were noted. ZNS may be both effective and well tolerated for the treatment of West syndrome.
Suzuki
Y
Y
Division of Pediatric Neurology, Osaka Medical Center and Research Institute for Maternal and Child Health, Murodo-cho, Izumi, Japan. yasuzuki@mch.pref.osaka.jp
Imai
K
K
Toribe
Y
Y
Ueda
H
H
Yanagihara
K
K
Shimono
K
K
Okinaga
T
T
Ono
J
J
Nagai
T
T
Matsuoka
T
T
Tagawa
T
T
Abe
J
J
Morita
Y
Y
Fujikawa
Y
Y
Arai
H
H
Mano
T
T
Okada
S
S
D000293:Adolescent; D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D007555:Isoxazoles / Q000009:adverse effects / Q000627:therapeutic use*; D008134:Long-Term Care / Q000706:statistics & numerical data; D008297:Male; D011446:Prospective Studies; D013036:Spasms, Infantile / Q000188:drug therapy*; D000078305:Zonisamide
D000927:Anticonvulsants; D007555:Isoxazoles; D000078305:Zonisamide